KPV Peptide Research Guide — Alpha-MSH Fragment, NF-κB Inhibition and Gut Biology

Research Use Only. All OL Research products are supplied strictly for in-vitro and laboratory research purposes. They are not medicines, food supplements, or cosmetic ingredients. Not for human or veterinary use. This article is written for educational and scientific reference only.

What is KPV?

KPV is a tripeptide consisting of the amino acids Lysine-Proline-Valine (Lys-Pro-Val). It represents the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH), a 13-amino-acid neuropeptide derived from proopiomelanocortin (POMC). Research has established that this short C-terminal fragment retains significant anti-inflammatory activity and can interact with melanocortin receptors and intracellular inflammatory mediators independently of the full-length α-MSH peptide.

KPV has a molecular weight of approximately 340.4 Da and is readily soluble in aqueous solution. Its small size confers potential for cellular internalisation — a property that has attracted research interest in gastrointestinal biology, where peptide access to subepithelial immune cells may be facilitated by transporter-mediated uptake.

Alpha-MSH and the Melanocortin System

To understand KPV’s research context, it is helpful to consider its parent molecule. α-MSH is a tridecapeptide produced by post-translational processing of POMC in the pituitary, skin, and central nervous system. It exerts anti-inflammatory effects through binding to melanocortin receptors (MCRs), particularly MC1R and MC3R, and by modulating the activity of pro-inflammatory transcription factors.

The C-terminal tripeptide KPV appears to recapitulate a substantial portion of this anti-inflammatory activity. Research suggests KPV may interact with melanocortin receptors at lower selectivity than full-length α-MSH, while also engaging intracellular pathways directly — possibly due to its ability to enter cells via peptide transporter PepT1, which is expressed on intestinal epithelial cells. This potential for direct intracellular access distinguishes KPV mechanistically from receptor-dependent pathways and has driven particular interest in its application to gut inflammation research.

NF-κB Inhibition and Anti-Inflammatory Mechanisms

The central mechanistic focus of KPV research is its reported ability to inhibit NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) signalling. NF-κB is a master transcription factor controlling the expression of a broad array of pro-inflammatory cytokines including TNF-α, IL-1β, IL-6, and IL-8, as well as adhesion molecules and enzymes such as COX-2 and iNOS. Its activation by pattern recognition receptors (TLRs), cytokines, and other stimuli is central to acute and chronic inflammatory responses.

In-vitro studies in intestinal epithelial cell lines (including Caco-2 and HT-29) and macrophage models have reported that KPV suppresses NF-κB nuclear translocation and reduces downstream cytokine production following stimulation with LPS or pro-inflammatory cytokines. Researchers typically quantify this using luciferase reporter assays (NF-κB-responsive promoter constructs), ELISA for secreted cytokines, and western blotting for phosphorylated IκB (the inhibitory protein whose degradation gates NF-κB activation).

Intestinal Inflammation Research

KPV has attracted particular attention in the context of intestinal inflammation, including models relevant to inflammatory bowel disease (IBD). The gastrointestinal epithelium provides a relevant experimental setting because PepT1 expression on colonocytes may facilitate KPV uptake into the epithelial cell interior, enabling direct suppression of intracellular inflammatory signalling without requiring surface receptor engagement.

Animal models of colitis — most commonly the dextran sodium sulphate (DSS) model in rodents — have been used to investigate KPV’s effects on intestinal inflammation. Outcome measures in these studies typically include histological inflammation scoring, colon length (a proxy for inflammation severity), myeloperoxidase (MPO) activity as a marker of neutrophil infiltration, and cytokine profiling of colonic tissue. Results have generally shown associations between KPV administration and reduced inflammatory markers, though model-to-model variation in results underscores the need for careful experimental design.

Researchers interested in gut biology may also wish to reference our BPC-157 research guide, which covers a distinct peptide with well-characterised gastrointestinal research applications, including mucosal healing and cytoprotective mechanisms.

Melanocortin Receptor Interactions

Beyond its potential intracellular activity, KPV has been investigated for direct melanocortin receptor binding. Binding affinity studies suggest KPV has affinity for MC1R and MC3R, though substantially lower than full-length α-MSH. MC1R is expressed on keratinocytes, melanocytes, and various immune cells, and its activation is associated with anti-inflammatory and immunomodulatory effects. MC3R is expressed centrally and peripherally and plays a role in energy homeostasis and immune modulation.

The extent to which receptor-mediated versus intracellular mechanisms account for KPV’s observed effects in specific experimental systems remains an active research question. Researchers using KPV alongside selective MCR agonists and antagonists can dissect these contributions experimentally.

Laboratory Use and Experimental Considerations

KPV is water-soluble and can be prepared in sterile PBS or aqueous solution for in-vitro use. Concentrations used in published research typically range from 1 μM to 100 μM in cell culture, with optimal concentrations being cell-type and assay dependent. For intestinal epithelial experiments, pre-treatment or co-treatment protocols with inflammatory stimuli (LPS, TNF-α, IL-1β) are standard approaches.

Researchers should note that tripeptides are subject to rapid proteolytic degradation in culture medium containing serum; the use of serum-reduced conditions or the addition of protease inhibitors at appropriate concentrations may be required for experiments requiring extended peptide exposure. Fresh preparation from lyophilised stock is recommended for each experimental session.

Related Research

For researchers interested in the broader melanocortin system, our guides on Melanotan II and PT-141 (Bremelanotide) provide detailed coverage of non-selective and central melanocortin receptor agonism respectively.